Clinical features and prognostic factors in Covid-19: A prospective cohort studySanne de Bruin, Anita M. Tuip‐de Boer, Alex R. Schuurman et al.|EBioMedicine|2021Cited by 137
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trialEndry H. T. Lim, Rutger Koning, Alexander P. J. Vlaar et al.|Respiratory Research|2022Cited by 18